Mesane karsinoma in situ farkındalığı

Özet

Mesane CIS, sistoskopide saptanması güç olabilen düz bir mukozal lezyondur. BT ürografi papiller kitle ve üst üriner sistem değerlendirmesinde yararlıdır, ancak mukozayla sınırlı CIS'yi göstermeyebilir; normal görünen mesane BT'si CIS'yi dışlamaz. Beyaz ışık sistoskopisi düz lezyonları, CIS dahil, gözden kaçırabilir; bu nedenle negatif inceleme CIS'yi tek başına dışlamaz. Mesane kanserinin doğrulanması ve evrelemesinde TURBT kullanılır; CIS şüphesinde haritalama biyopsileri değerlendirilebilir.

Faz ve pencere

Nefrografik

Belirgin kontrastlanan papiller kitle varsa görünür; düz mukozal CIS için özgül bir kontrastlanma bulgusu olmayabilir. Negatif nefrografik görüntü CIS’yi dışlamaz.

Ekskretuar

Opak idrarla dolan mesanede belirgin intralüminal dolum defekti bulunmayabilir; düz CIS görüntüleme ile saptanamayabilir ve tanı sistoskopi/biopsi ile doğrulanır.

Önerilen pencereler: Batın (G 400 / M 50), Yumuşak doku (G 400 / M 40).

BT bulguları

• Düz mukozal lezyon kontrastlı BT'de görünür kitle oluşturmayabilir.
• Mesane duvar kalınlaşması belirgin kitle olmaksızın görülebilir.
• Düz CIS lezyonları beyaz ışık sistoskopisinde gözden kaçabilir.
• Sistoskopi bulguları kuşkuluysa veya CIS riski varsa idrar sitolojisi seçilmiş hastalarda yardımcı olabilir; CIS’yi dışlamak için haritalama biyopsileri kullanılabilir.
• İdrar sitolojisi, CIS dahil yüksek dereceli ürotelyal tümörlerin saptanmasında yardımcı olabilir.

Ölçütler ve sınıflamalar

Tis: Karsinomato in situ (CIS)

Tis, düz (yassı) ürotelyal karsinoma in situ kategorisidir; görüntüleme Tis tanısı koymaz ve histopatolojik değerlendirme gerekir.

Normalde

Normal BT'de iyi distandü mesane duvarı düzgün ve simetrik görünür; CIS bulunan mesane de aynı görünüme sahip olabilir.

Ayırıcı tanı

Papiller ürotelyal karsinom

lümene uzanan kontrastlanan yumuşak doku veya dolum defekti oluşturabilir.

Sistit

yaygın düzgün duvar kalınlaşması ve klinik inflamasyon bulguları görülebilir; BT görünümü CIS'ye özgü değildir.

Trabekülasyon

kronik çıkış obstrüksiyonunda çok odacıklı düzensiz duvar konturu yapar.

TURBT veya intravezikal tedavi sonrası değişiklikler mpMR görüntülemede rezidü tümörü taklit edebilir.

Tuzaklar

• Normal BT raporunu CIS yokluğu şeklinde yorumlamayın; ince düz mukozal hastalık BT'nin uzaysal ve kontrast çözünürlüğünün altında kalabilir.
• Düz lezyonlar beyaz ışık sistoskopisinde gözden kaçabilir; mesane kanseri TURBT ile doğrulanır ve evrelenir.

Kendini dene

1. Beyaz ışık sistoskopisinde belirgin düz lezyon görülmüyor. Bu bulgu CIS'yi dışlar mı?

   • CIS dışlanamaz
   • CIS kesinleşir
   • Papiller tümör kanıtlandı
   • Mesane normal kabul edilir
   Cevabı göster

   CIS dışlanamaz. Beyaz ışık sistoskopisi düz lezyonları, CIS dahil, gözden kaçırabilir. Mesane kanseri TURBT ile doğrulanır ve evrelenir.

2. Mesane kanserinin tanısının doğrulanması ve evrelemesi için hangi işlem kullanılır?

   • Transüretral mesane tümörü rezeksiyonu (TURBT)
   • BT ürografi
   • Beyaz ışık sistoskopisi
   • İdrar sitolojisi
   Cevabı göster

   Transüretral mesane tümörü rezeksiyonu (TURBT). Mesane kanseri TURBT ile doğrulanır ve evrelenir.

İlgili konular

• Mesane ürotelyal karsinomu
• İntraperitoneal mesane rüptürü
• Ekstraperitoneal mesane rüptürü
• BT sistografi ve mesane dolum tekniği

Kaynaklar

Bu sayfadaki 32 cümle ve 2 quiz sorusu aşağıdaki kaynaklardan alıntılarla otomatik olarak karşılaştırıldı; 16 cümle bu karşılaştırmada düzeltildi (2026-10-09).

1. Inflammatory Myofibroblastic Tumor of the Urinary Bladder Presenting as a Radiological cT3 Mass: A Case Report and Narrative Review of 89 Casespmc.ncbi.nlm.nih.gov
2. Missed Diagnosis of Clear Cell Renal Cell Carcinoma on Noncontrast Computed Tomography: The Potential Role of Artificial Intelligence in Reducing Radiological Diagnostic Errorpmc.ncbi.nlm.nih.gov
3. Evaluating 18 F-FDG PET-CT for Regional Lymph Node Assessment in Advanced Upper Tract Urothelial Carcinomapmc.ncbi.nlm.nih.gov
4. Submucosal urothelial cancer of bladder: A case reportpmc.ncbi.nlm.nih.gov
5. Late-Onset Metastatic Signet Ring Cell Adenocarcinoma Following Bladder Exstrophy Reconstruction: Diagnostic Discordance and Uncertain Primary Originpmc.ncbi.nlm.nih.gov
6. Consultation on UTUC, Stockholm 2018 aspects of diagnosis of upper tract urothelial carcinoma.pubmed.ncbi.nlm.nih.gov
7. Feasibility study of toxicity outcomes using GEC-ESTRO contouring guidelines on CT based instead of MRI-based planning in locally advanced cervical cancer patients.pubmed.ncbi.nlm.nih.gov
8. Roles for epigenetic and other biomarkers in upper tract urothelial carcinoma diagnosis and surveillance.pubmed.ncbi.nlm.nih.gov
9. Artificial intelligence advances in cystoscopy and imaging for bladder cancer: a narrative review.pubmed.ncbi.nlm.nih.gov
10. Upper Tract Urothelial Carcinoma: An Update on Current Diagnostic Modalities and Emerging Biomarkers.pubmed.ncbi.nlm.nih.gov
11. Comparison of Automated Urinalysis Parameter Atyp.C and Urine Cytology for Detecting Bladder Carcinoma <i>In Situ</i>.pubmed.ncbi.nlm.nih.gov
12. Under-reporting of carcinoma in situ in patients with high-grade papillary non-muscle-invasive bladder cancer.pubmed.ncbi.nlm.nih.gov
13. Integrating Molecular Classification Based on FGFR3, KRAS, HRAS, and TP53 Mutation With TNM Staging Modestly Improves Prediction of Prognosis of Upper Tract Urothelial Carcinoma After Surgery.pubmed.ncbi.nlm.nih.gov
14. Enhanced Imaging in Bladder Cancer: Fluorescence Cystoscopy and Molecular Diagnostics.pubmed.ncbi.nlm.nih.gov
15. Enhanced Endoscopic Imaging Technologies in Upper Urinary Tract Urothelial Tumors: Implications for Kidney-Sparing Surgery-A Narrative Review.pubmed.ncbi.nlm.nih.gov
16. Bladder mucosal apoptosis index and quality of life after adjuvant intravesical BCG therapy for non-muscle-invasive bladder cancer: a retrospective propensity-score-matched study.pubmed.ncbi.nlm.nih.gov
17. Evaluating the Role of Urine Cytology in Haematuria One-Stop Clinics: A Scoping Review of Current Evidence and Clinical Utility.pubmed.ncbi.nlm.nih.gov
18. Diagnostic Performance of Biomarkers for Bladder Cancer Detection Suitable for Community and Primary Care Settings: A Systematic Review and Meta-Analysis.pubmed.ncbi.nlm.nih.gov
19. KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors.pubmed.ncbi.nlm.nih.gov
20. BK Polyomavirus-Associated Urothelial Carcinoma Presenting as Obstructive Uropathy in a Long-Term Lung Transplant Recipient.pubmed.ncbi.nlm.nih.gov
21. Urinary Biomarkers in Urological Oncology: From Biological Origin to Clinical Decision-Making-A Narrative Review.pubmed.ncbi.nlm.nih.gov
22. Case Report: Radical nephroureterectomy after toripalimab plus disitamab vedotin in biomarker-non-enriched upper tract urothelial carcinoma.pubmed.ncbi.nlm.nih.gov
23. Biopsy-Proven Prostatic Metastasis From Diffuse-Type Gastric Adenocarcinoma Presenting With Bilateral Malignant Ureteric Obstruction: A Case Report.pubmed.ncbi.nlm.nih.gov
24. Multifocal xanthogranulomatous inflammation of the urinary tract mimicking metastatic urothelial carcinoma: A case report.pubmed.ncbi.nlm.nih.gov
25. The role of MRI in detection and staging of upper urinary tract cancer: a systematic review of the literature.pubmed.ncbi.nlm.nih.gov
26. Conduit Bleeding Unmasks Isolated Distal Ureter Recurrence After Radical Cystectomy: Lessons in Laparoscopic Nephroureterectomy and Surveillance.pubmed.ncbi.nlm.nih.gov
27. Centripetal filling and pathological insights: a rare case of sporadic renal hemangioblastoma with literature review.pubmed.ncbi.nlm.nih.gov
28. Cosmic Signs in Radiology: A Pictorial Review.pubmed.ncbi.nlm.nih.gov
29. Diagnostic Yield of Upper-Tract Imaging in Visible Haematuria: A Single-Centre Retrospective Clinical Audit.pubmed.ncbi.nlm.nih.gov
30. Imaging in Upper Tract Urothelial Carcinoma: A Review.pubmed.ncbi.nlm.nih.gov
31. Kidney-sparing approach for upper tract urothelial carcinoma: An update on current evidence.pubmed.ncbi.nlm.nih.gov
32. Asymptomatic bilateral renal granulomas following intravesical BCG immunotherapy for bladder cancer: a case report.pubmed.ncbi.nlm.nih.gov
33. Bladder tumors in patients initially diagnosed with interstitial cystitis: a ten-year retrospective study.pubmed.ncbi.nlm.nih.gov
34. Diagnostic challenges in a rare case of bladder metastasis from lung hepatoid adenocarcinoma: The first reported case.pubmed.ncbi.nlm.nih.gov
35. Pembrolizumab-Associated Immune-Related Cystitis Mimicking Urothelial Malignancy as Part of a Multi-organ Immune-Related Adverse Event (irAE) Phenotype in a Patient With Metastatic Squamous Cell Lung Cancer: A Case Report and Literature Review.pubmed.ncbi.nlm.nih.gov
36. Gallbladder Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma With Gallstone Pancreatitis and Prostate Cancer.pubmed.ncbi.nlm.nih.gov
37. Postmenopausal bladder endometriosis without exogenous estrogen: a case report and literature review.pubmed.ncbi.nlm.nih.gov
38. Unveiling an Inverted Papilloma of the Bladder: A Case Series and Literature Review.pubmed.ncbi.nlm.nih.gov
39. Robot-assisted nephroureterectomy in a patient with left-sided inferior vena cava: a case report.pubmed.ncbi.nlm.nih.gov
40. Delivery of Multifunctional Microspheres via Intravesical Instillation for Bladder Carcinoma: Therapeutic Potential and Mechanistic Insights.pubmed.ncbi.nlm.nih.gov
41. Urothelial carcinoma with trophoblastic differentiation: case report and review of literature.pubmed.ncbi.nlm.nih.gov
42. Rapidly Progressive Retroperitoneal Dissemination of Plasmacytoid Urothelial Carcinoma Presenting With Multiorgan Obstruction After Radical Cystectomy: A Case Report.pubmed.ncbi.nlm.nih.gov
43. Early detection of gallbladder cancer: Current status and future perspectives.pubmed.ncbi.nlm.nih.gov
44. Basic Clinical Bidirectional Empowerment: Synergistic Breakthrough in Molecular Mechanisms and Clinical Management of Small Cell Cervical Carcinoma.pubmed.ncbi.nlm.nih.gov
45. Capsular Contracture in Implant-Based Breast Reconstruction: A Comprehensive Narrative Review of Pathophysiology, Risk Factors, and Contemporary Controversies.pubmed.ncbi.nlm.nih.gov
46. Contrast-enhanced ultrasound-guided biopsy and perfusion monitoring for bladder involvement in relapsed multiple myeloma: a case report.pubmed.ncbi.nlm.nih.gov
47. Real-world outcomes of definitive chemoradiotherapy for bladder cancer: a multi-institutional retrospective study in Japan.pubmed.ncbi.nlm.nih.gov
48. Transcriptomic profiling across stages of non-muscle-invasive bladder cancer identifies fibroblast activation protein-alpha as a stromal biomarker associated with progression.pubmed.ncbi.nlm.nih.gov
49. Diuretic-Enhanced Dual-Phase F-18 FDG PET/CT: A New Window Into Muscle-Invasive Bladder Cancer.pubmed.ncbi.nlm.nih.gov
50. TERT promoter C228T and C250T mutation detection combined with cytology in the diagnosis of urothelial carcinomas: a real-world cohort study in a Chinese population.pubmed.ncbi.nlm.nih.gov
51. Correlation Between the Natural Course and Magnetic Resonance Imaging Features of Bacillus Calmette-Guérin-Related Granulomatous Prostatitis in Patients With Bladder Cancer.pubmed.ncbi.nlm.nih.gov
52. Epidermoid Cyst of the Ureter Mimicking Recurrent Urothelial Carcinoma: A Case Report and Brief Literature Review.pubmed.ncbi.nlm.nih.gov
53. Obstructive lower urinary tract symptoms due to ball valve effect of a rare bladder tumor in an adolescent male.pubmed.ncbi.nlm.nih.gov
54. Upper Urinary Tract Carcinoma With Primary Small Cell Neuroendocrine Cancer-Case Report and Review of Literature.pubmed.ncbi.nlm.nih.gov
55. Primary small-cell neuroendocrine carcinoma of the bladder: a very rare histological subtype.pubmed.ncbi.nlm.nih.gov
56. Severe Lower Urinary Tract Dysfunction in Otherwise Healthy Children: A Three-Case Series and Narrative Review.pubmed.ncbi.nlm.nih.gov
57. CT and MRI in Urinary Tract Infections: A Spectrum of Different Imaging Findings.pubmed.ncbi.nlm.nih.gov
58. The Role of Imaging in Bladder Cancer Diagnosis and Staging.pubmed.ncbi.nlm.nih.gov
59. EACR 2025 Congress: Innovative Cancer Science, 16-19 June 2025.pubmed.ncbi.nlm.nih.gov
60. High-intensity focused ultrasound treatment for advanced pancreatic cancer.pubmed.ncbi.nlm.nih.gov
61. Klippel-Trénaunay Syndrome With Pelvic/Rectal and Urinary Bladder Involvement: A Rare Case Report.pubmed.ncbi.nlm.nih.gov
62. Pitfalls and Limitations of the Vesical Imaging-Reporting and Data System (VI-RADS): Challenges in the Multiparametric Magnetic Resonance Imaging (mpMRI) Assessment of Bladder Cancer.pubmed.ncbi.nlm.nih.gov
63. Diagnostic and Prognostic Non-Invasive Markers in Bladder Cancer.pubmed.ncbi.nlm.nih.gov
64. Dose-painting after multi-block endoscopic endonasal surgery in sinonasal tumours: protocol for the SinocaRT randomised phase II trial.pubmed.ncbi.nlm.nih.gov
65. Urine-Based Approaches for Screening, Diagnosis, and Surveillance of Urothelial Carcinoma.pubmed.ncbi.nlm.nih.gov
66. FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ.pubmed.ncbi.nlm.nih.gov
67. Approximation of urinary bladder volume with few measurements on cross-sectional imaging.pubmed.ncbi.nlm.nih.gov
68. Computed Tomographic Findings and Clinical Manifestations of Acute Severe Hypersensitivity to a Non-Ionic Iodinated Contrast Agent in a Castrated Male Dog: A Case Report.pubmed.ncbi.nlm.nih.gov
69. Preliminary feasibility and safety of domestic probe-based confocal laser endomicroscopy in the diagnosis of bladder lesions: a prospective single-arm cohort study.pubmed.ncbi.nlm.nih.gov
70. Study of Bladder Cancer Detection in Standard White Light Versus AI-Supported Endoscopy-02 (RAISE-02)-A Randomized Controlled Non-Inferiority Trial.pubmed.ncbi.nlm.nih.gov
71. Primary sarcomatoid urothelial carcinoma of the ureter: A case report and literature review.pubmed.ncbi.nlm.nih.gov
72. Bacillus Calmette-Guérin therapy in the management of upper tract urothelial carcinoma in-situ: a systematic review.pubmed.ncbi.nlm.nih.gov
73. Single center evaluation of sensitivity and specificity of CellDetect assay in early bladder cancer patients.pubmed.ncbi.nlm.nih.gov
74. Development and prospective validation of a multitarget urine RNA assay for noninvasive detection of urothelial carcinoma.pubmed.ncbi.nlm.nih.gov
75. Artificial intelligence and predictive tools in non-muscle invasive bladder cancer: a narrative review of current insights and advances.pubmed.ncbi.nlm.nih.gov
76. Large multicenter validation of urine RNA profile for urothelial carcinoma detection and surveillance.pubmed.ncbi.nlm.nih.gov
77. Progress in the application of combined detection of urinary tumor DNA and exosomes in the classification, staging, and clinical management of bladder cancer: a review.pubmed.ncbi.nlm.nih.gov
78. Intraductal papillary mucinous neoplasm-derived pancreatic cancer of the ventral duct in patient with pancreas divisum: a case report.pubmed.ncbi.nlm.nih.gov
79. Fistulating Intraductal Papillary Mucinous Neoplasms (IPMNs): Case Series and Discussion of a Rare Complication.pubmed.ncbi.nlm.nih.gov
80. Primary Neoplasms of the Seminal Vesicles: A Narrative Review of Carcinoma and the Rarer Non-Epithelial and Biphasic Tumours.pubmed.ncbi.nlm.nih.gov
81. Inflammatory Myofibroblastic Tumor of the Urinary Bladder Presenting as a Radiological cT3 Mass: A Case Report and Narrative Review of 89 Cases.pubmed.ncbi.nlm.nih.gov
82. A multidisciplinary FEVAR and stent graft repair to exclude mycotic aneurysms by interventional radiology and vascular surgery: Case report.pubmed.ncbi.nlm.nih.gov
83. Metastatic Small Cell Neuroendocrine Carcinoma of the Prostate: A Rare and Aggressive Case Report From Bangladesh.pubmed.ncbi.nlm.nih.gov
84. IL-12 as a Potential Prognostic Marker in Penile Cancer: Implications for Immune Dysregulation.pubmed.ncbi.nlm.nih.gov
85. Unveiling the immune microenvironment in sinonasal intestinal type adenocarcinoma: new arguments for immunotherapy.pubmed.ncbi.nlm.nih.gov
86. Bridging the evidence gap: three-year BCG maintenance therapy shows enhanced protection over one-year regimen in Chinese NMIBC.pubmed.ncbi.nlm.nih.gov
87. Long pedunculated tumor from the ureteral stump protruding into the bladder after nephrectomy: a case report.pubmed.ncbi.nlm.nih.gov
88. Small cell carcinoma in a bladder diverticulum: a rare case report and literature review.pubmed.ncbi.nlm.nih.gov
89. Renal clear cell carcinoma with co-existing tumor thrombosis of renal vein and ureter: a case report and review of the literature.pubmed.ncbi.nlm.nih.gov
90. Population Pharmacokinetics and Exposure-Response of Sasanlimab, a Checkpoint Inhibitor, in Patients with Non-Muscle Invasive Bladder Cancer and Other Solid Tumors.pubmed.ncbi.nlm.nih.gov
91. Xpert bladder cancer detection and monitor in urothelial carcinoma: systematic review and meta-analysis.pubmed.ncbi.nlm.nih.gov
92. Current opinions regarding the clinical utility of en bloc resection in the treatment of non-muscle invasive bladder cancer-a review of the literature.pubmed.ncbi.nlm.nih.gov
93. Clinical utility of urinary comprehensive genomic profiling in diagnosing metachronous upper tract urothelial carcinoma: a case report.pubmed.ncbi.nlm.nih.gov
94. Synchronous Prostate Adenocarcinoma and Bladder Carcinoma In Situ Detected During Evaluation of Incidental PSA Elevation: A Case Report Illustrating Multimodal Diagnostic Correlation and Long-Term Follow-Up.pubmed.ncbi.nlm.nih.gov
95. A case of prostatic urothelial carcinoma with aggressive metastasis: Magnetic resonance imaging as an initial diagnostic clue.pubmed.ncbi.nlm.nih.gov
96. Paired Urinary Cytology and Targeted FGFR3 S249C/R248C Mutation Detection in Urine from Patients with Bladder Cancer: A Pilot Study.pubmed.ncbi.nlm.nih.gov
97. A Rare Case of a Non-Invasive Vaginal Urothelial Carcinoma Demonstrating a Clonal Relationship With a Metachronous Non-Invasive Bladder Urothelial Carcinoma.pubmed.ncbi.nlm.nih.gov
98. BCG after trimodality therapy: managing non-muscle-invasive recurrence in the irradiated bladder.pubmed.ncbi.nlm.nih.gov
99. 5-Aminolevulinic Acid-Based Fluorescence Guidance in Urologic Oncology: Current Status, Pitfalls, and Future Directions.pubmed.ncbi.nlm.nih.gov
100. Liquid biopsy-guided kidney-sparing management in upper tract urothelial carcinoma: from preoperative risk stratification to perioperative surveillance.pubmed.ncbi.nlm.nih.gov
101. Clinical Significance, Differential Diagnosis and Initial Management of Hematuria in Emergency and Outpatient Settings.pubmed.ncbi.nlm.nih.gov
102. Imaging Tips and Tricks in Management of Renal and Urothelial Malignancies.pubmed.ncbi.nlm.nih.gov
103. Imaging and Management of Bladder Cancer.pubmed.ncbi.nlm.nih.gov
104. A Case Report of an Unusual Cause of Abnormal Uterine Bleeding: Primary Cervical Lymphoma Misdiagnosed As Hormonal Dysfunction.pubmed.ncbi.nlm.nih.gov
105. Role of Multiparametric MR Imaging in Malignancies of the Urogenital Tract.pubmed.ncbi.nlm.nih.gov
106. Inflammatory bowel disease imaging: Current practice and future directions.pubmed.ncbi.nlm.nih.gov
107. Partial Cystectomy for Muscle-Invasive Bladder Cancer.pubmed.ncbi.nlm.nih.gov
108. Optimizing the Diagnosis of Interstitial Cystitis/Bladder Pain Syndrome: An ESSIC Proposal.pubmed.ncbi.nlm.nih.gov
109. Evaluating ¹⁸F-FDG PET-CT for Regional Lymph Node Assessment in Advanced Upper Tract Urothelial Carcinoma.pubmed.ncbi.nlm.nih.gov
110. Spectral CT findings of bladder urothelial carcinoma with gastric metastasis: a case report.pubmed.ncbi.nlm.nih.gov
111. Urinary bladder: normal appearance and mimics of malignancy at CT urography.pubmed.ncbi.nlm.nih.gov
112. A Rare Case of Bladder Melanosis: A Case Report and Review of the Literature.pubmed.ncbi.nlm.nih.gov
113. Diagnosis, evaluation, and management of patients with non-muscle invasive bladder cancer.pubmed.ncbi.nlm.nih.gov
114. Urothelial carcinoma in a urinary bladder diverticulum: A case report and review of the literature.pubmed.ncbi.nlm.nih.gov
115. Bladder's Blind Spot: A Rare Case of Non-bilharzial Diverticular Squamous Cell Carcinoma Treated With Partial Cystectomy.pubmed.ncbi.nlm.nih.gov

Eğitim amaçlıdır; hasta başında tanı ve tedavi kararının yerine geçmez, tıbbi tavsiye değildir. Metinler yapay zekâ desteğiyle yazıldı ve otomatik bir adımda kaynak alıntılarıyla karşılaştırıldı; bu bir tıbbi doğrulama değildir ve içerik uzman radyolog incelemesinden geçmedi. Klinik kararlarda güncel kılavuzları, kurum protokollerini ve radyoloji raporunu esas alın.